Genmab — Juni 2022
-
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta
(ofatumumab) had no evidence of disease activity (NEDA-3) https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3 -
Transactions in connection with share buy-back program https://ir.genmab.com/news-releases/news-release-details/transactions-connection-share-buy-back-program-17
-
Thanks E L.
-
God morgen.
-
God morgen. Nyt STÆRKT TA købssignal. Bullish udvikling op mod 2661 modstandsområdet. 85% sandsynlighed. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/104233_Skaermbillede_2022_06_28_134152_2661.jpg
-
Biotech Stocks Facing FDA Decision In July 2022 https://www.proinvestor.com/investornyt/843364/biotech-stocks-facing-fda-decision-in-july-2022
-
Aktier/middag: SAS i hopla efter norsk tilsagn - medicinal tynger C25
https://www.proinvestor.com/investornyt/843378/aktier-middag-sas-i-hopla-efter-norsk-tilsagn-medicinal-tynger-c25 -
USA/åbning: Banker og tech sendes op i grønt marked - Nike falder
https://www.proinvestor.com/investornyt/843526/usa-abning-banker-og-tech-sendes-op-i-gront-marked-nike-falder -
NEW TRIAL: A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy https://www.clinicaltrials.gov/ct2/show/NCT05435339
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind